izpis_h1_title_alt

Nanomedicine and immunotherapy : a step further towards precision medicine for glioblastoma
ID Šamec, Neja (Author), ID Zottel, Alja (Author), ID Videtič Paska, Alja (Author), ID Jovchevska, Ivana (Author)

.pdfPDF - Presentation file, Download (1,18 MB)
MD5: A8EEDC0CE330B7D661E75D9FE7B5CD48
URLURL - Source URL, Visit https://www.mdpi.com/1420-3049/25/3/490 This link opens in a new window

Abstract
Owing to the advancement of technology combined with our deeper knowledge of human nature and diseases, we are able to move towards precision medicine, where patients are treated at the individual level in concordance with their genetic profiles. Lately, the integration of nanoparticles in biotechnology and their applications in medicine has allowed us to diagnose and treat disease better and more precisely. As a model disease, we used a grade IV malignant brain tumor (glioblastoma). Significant improvements in diagnosis were achieved with the application of fluorescent nanoparticles for intraoperative magnetic resonance imaging (MRI), allowing for improved tumor cell visibility and increasing the extent of the surgical resection, leading to better patient response. Fluorescent probes can be engineered to be activated through different molecular pathways, which will open the path to individualized glioblastoma diagnosis, monitoring, and treatment. Nanoparticles are also extensively studied as nanovehicles for targeted delivery and more controlled medication release, and some nanomedicines are already in early phases of clinical trials. Moreover, sampling biological fluids will give new insights into glioblastoma pathogenesis due to the presence of extracellular vesicles, circulating tumor cells, and circulating tumor DNA. As current glioblastoma therapy does not provide good quality of life for patients, other approaches such as immunotherapy are explored. To conclude, we reason that development of personalized therapies based on a patient’s genetic signature combined with pharmacogenomics and immunogenomic information will significantly change the outcome of glioblastoma patients.

Language:English
Keywords:glioblastoma, extracellular vesicles, nanoscience, cell free DNA, circulating tumor DNA, liquid biopsy, immunotherapy
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2020
Number of pages:33 str.
Numbering:Vol. 25, iss. 3, art. 490
PID:20.500.12556/RUL-133241 This link opens in a new window
UDC:577
ISSN on article:1420-3049
DOI:10.3390/molecules25030490 This link opens in a new window
COBISS.SI-ID:34662361 This link opens in a new window
Publication date in RUL:18.11.2021
Views:1228
Downloads:134
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Molecules
Shortened title:Molecules
Publisher:MDPI
ISSN:1420-3049
COBISS.SI-ID:18462981 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.02.2020

Secondary language

Language:Slovenian
Keywords:glioblastom, zunajcelični vezikli, nanoznanost

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0390
Name:Funkcijska genomika in biotehnologija za zdravje

Funder:ARRS - Slovenian Research Agency
Funding programme:Young Researcher Grant

Funder:ARRS - Slovenian Research Agency
Project number:Z3-1869
Name:Razvoj anti-FREM2 nanotelesa in njegova uporaba pri ciljanju glioblastomskih celic

Funder:EC - European Commission
Funding programme:Interreg
Project number:146
Acronym:TRANS-GLIOMA

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back